Compounds and methods of treating usher syndrome III
An isolated polynucleotide includes a nucleic acid sequence that includes a cDNA coding sequence of a clarin-1 gene and a 3′UTR nucleic acid that is derived from the 3′UTR of the clarin-1 gene. The 3′UTR nucleic acid can enhance expression of clarin-1 in a cell transfected with the polynucleotide compared to a cell transfected with a similar polynucleotide devoid of the 3′UTR nucleic acid.
1. A method of slowing the progression of hearing loss in a mammalian subject predisposed or having a progressive hearing loss associated with Usher syndrome III, the method comprising:
administering directly to cells of the inner ear of the subject a therapeutically effective amount of a recombinant adeno-associated viral vector that promotes expression of wild-type clarin-1 in the cells, the vector comprising a wild-type clarin-1 cDNA coding sequence having a 5′ end and a 3′ end that is flanked at the 5′ end with full-length 5′UTR nucleic acid sequence of the clarin-1 gene and at the 3′ end with full-length 3′UTR nucleic acid sequence of the clarin-1 gene, wherein the 5′UTR and the 3′UTR nucleic acid sequences enhance expression of clarin-1 in a cell transfected with the vector compared to a cell transfected with a vector that includes a wild-type clarin-1 cDNA coding sequence devoid of the 5′UTR and 3′UTR nucleic acid sequences, and wherein said administering is prior to the onset of hair cell degeneration in said subject.
2. The method of claim 1 , the 3′UTR nucleic acid comprising SEQ ID NO: 5.
3. The method of claim 1 , the clarin-1 cDNA having the sequence identity of SEQ ID NO: 3 or SEQ ID NO: 4.
4. The method of claim 1 , the vector comprising a nucleic acid sequence having the sequence identity of SEQ ID NO: 1 or SEQ ID NO: 2.